Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PPG Industries, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while PPG Industries, Inc. trades at $114.27 (market cap $26.80B). The key difference: PPG Industries, Inc. is far larger — about 6× ACADIA Pharmaceuticals Inc.'s market cap, and PPG Industries, Inc. pays a 2.36% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PPG | |
|---|---|---|
Market Cap | $4.49B | $26.80B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $131.56 |
52-Week Low | $20.06 | $94.34 |
Enterprise Value | $3.69B | $32.90B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PPG Industries (PPG) trades at $120.22, down 4.08% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings of $1.83 per share, beating estimates, and maintains solid profitability with a net margin of 9.83% and ROE of 21.09%. Recent news highlights innovation in aerospace and marine coatings, including a green chemistry award for SIGMAGLIDE 2390 coating.
The outlook is supported by analyst consensus with a $129.40 price target and 52.63% buy ratings, but risks include volume softness and margin pressure. Earnings growth and sustainability initiatives are key catalysts, though macroeconomic headwinds and competitive pressures remain concerns for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
